HomeAI · summaries
Storia in 11 fonti
Generic drugmaker Sandoz to engage with US after Trump tariff threat
US President Donald Trump threatened steep tariffs on generic drugmakers. He stated medicines must be manufactured locally or face significant import duties. Swiss firm Sandoz will continue discussions with policymakers on this matter. The company is assessing implications for its manufacturing operations and future investments. This move aims to reverse offshore production and could increase drug prices.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Trump threatens tariffs on imported generic drugs
While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the…
- ·
timesofindia.indiatimes.com
Trump announces 0% tariff on generic medicines for two years; 200% thereafter
US President Donald Trump on Tuesday announced a phased tariff regime on imported generic medicines, saying they will continue to enter the United States duty-free for two years…
- ·
economictimes.indiatimes.com
Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%
Trump has been pressuring drugmakers through his most-favored-nation drug pricing policy to lower prices to what people pay in other high-income countries.
- ·
hindustantimes.com
US to impose steep tariffs on generic medicine imports from Aug 2028
US to impose steep tariffs on generic medicine imports from Aug 2028
- ·
france24.com
Trump announces 100% tariffs on imported generic pharmaceutical drugs
US President Donald Trump announced a 100% tariff on imported generic pharmaceutical drugs on Tuesday. The tariff, which aims to bolster US pharmaceutical production, is set to go…
- ·
malaymail.com
Trump imposing 100pc tariff on generic drugs from August 2028
WASHINGTON, July 22 — US President Donald Trump announced yesterday the imposition of steep tariffs on imported generic drugs from August 2028, a move he said was aimed at...
- ·
Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028
Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption…
- ·
nzz.ch
Trump droht jetzt mit Generika-Zöllen von 200 Prozent - auch Sandoz wäre betroffen
Der führende Generika-Hersteller aus Basel hat bisher darauf verzichtet, neue Fabriken in den USA zu bauen. Die Schweizer Auftragsfertiger sind dagegen schon in Amerika präsent…
- ·
newsbytesapp.com
Trump threatens tariff on generic medicines: Should India be worried?
US President Trump announced a two-year tariff exemption for imported generic medicines, warning of steep 200% duties if production doesn't shift to the US afterward.
- ·
swissinfo.ch
Trump’s 100% Generic Drug Duty Threatens US Low-Cost Supply
(Bloomberg) -- Generic drug manufacturers will have two years to move production to the US or face a 100% import duty from August 2028, President Donald Trump said, threatening…
- ·
0, 100, 200: How Trump's latest generic medicines tariffs could affect India
Indian drugmakers export around $9-10 billion worth of generic medicines to the American market every year. | India News
- ·
Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm
Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After…
- ·
rsi.ch
Trump: dazi zero sui generici, poi aumenti massicci - RSI
Trump annuncia dazi zero sui farmaci generici fino al 2028, poi tariffe al 100% e 200%. Sandoz reagisce con cautela: scopri l'impatto sull'industria farmaceutica.
- ·
Trump’s 100% generic drug duty threatens US low-cost supply
President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…
- ·
200% Trump tariff shock? India’s cheap pills may still beat US rivals
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…
- ·
Indian pharma firms may yet survive Trump's 200% tariff bombshell
Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…
- ·
Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors
Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be…
- ·
Swiss pharma firm Sandoz takes note of proposed US tariffs on generic drugs
Generic drugs giant Sandoz said on Wednesday that it had “taken note” of Washington’s announcements regarding new tariffs of up to 200%.
- ·
letemps.ch
Les menaces de Donald Trump sur les génériques placent Sandoz en première ligne - Le Temps
L’offensive protectionniste de Donald Trump vise à rapatrier la production de médicaments génériques aux Etats-Unis. Une perspective qui pourrait particulièrement compliquer la…
- ·
Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive
In a blow to India’s pharmaceutical industry, the Donald Trump administration has announced up to 200% tariffs on generic drugs that will be applicable in the coming years.